Biotech Short Candidates Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Short Candidates

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who wrote (509)	5/14/2003 2:01:48 PM
From: Icebrg	Read Replies (1) of 897

>>And what do folks think of Xolair's (TNOX, DNA) chances for approval, given the safety profile and cost?>> The price doesn't matter for the approval, I believe. FDA cannot refuse to approve a drug because of the price if the price hasn't even been set yet. I don't think that a cancer risk that is so small that it cannot even be measured will preclude approval in this case. There are other approved drugs which carries similar risks. Like Remicade, Enbrel et. al. The best way to short these companies seems btw. to be to do it on the day before the day before the meeting. Because the day before the meeting FDA will publish their findings and they are "always" very negative. Which will be negative for weak stocks. Scary people working at that agency - they behave like prosecutors and perhaps that is their role. As for DNA - I don't think it will really matter. ASCO is more important for them.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next